预约演示
更新于：2026-04-14
Abiraterone acetate
醋酸阿比特龙
更新于：2026-04-14
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2011-04-28), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C26H33NO2 |
InChIKeyUVIQSJCZCSLXRZ-UBUQANBQSA-N |
CAS号154229-18-2 |
关联
393
项与 醋酸阿比特龙 相关的临床试验CTIS2025-524440-35-00
Standard dosed abiraterone versus Therapeutic Drug Monitoring guided abiraterone dosing – The Adapt Abi trial
JPRN-UMIN000021079
Upfront abiraterone and docetaxel administration in patients with high-risk metastatic hormone-naive prostate cancer - UFAD in mHNPC
NCT07190300
TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combination With Darolutamide Versus Darolutamide Alone in Patients With Metastatic Hormone-sensitive Prostate Cancer
100 项与 醋酸阿比特龙 相关的临床结果
登录后查看更多信息
100 项与 醋酸阿比特龙 相关的转化医学
登录后查看更多信息
100 项与 醋酸阿比特龙 相关的专利（医药）
登录后查看更多信息
3,276
项与 醋酸阿比特龙 相关的文献（医药）2026-09-26ENDOCRINE-RELATED CANCER
Body composition in recurrent prostate cancer and the role of steroidogenic genotype
Article
作者: Pilie, Patrick G ; Mukhida, Sagar S ; Corn, Paul G ; Koutroumpakis, Efstratios ; McQuade, Jennifer L ; Tidwell, Rebecca S ; Gregg, Justin R ; Zurita, Amado J ; Aparicio, Ana ; Hahn, Andrew W ; Frigo, Daniel E ; Huff, Chad ; Logothetis, Christopher J ; Subudhi, Sumit K ; Siddiqui, Bilal A ; Venkatesh, Neha ; Yu, Yao
Hormone therapy (HT) to treat prostate cancer is reported to cause adverse changes in body composition. Clinically, interpatient body composition changes are heterogeneous, but the biological and clinical determinants of body composition toxicity are unknown. Herein, we test the hypothesis that inherited polymorphisms in steroidogenic genes are associated with differential changes in body composition after HT. Men with biochemically recurrent prostate cancer (BCR) who received 8 months of LHRH analog (LHRHa) +/− abiraterone acetate (AAP) were eligible if they had: i) CT imaging of L3 prior to and after treatment; and ii) nucleated cells collected. Cardiometabolic co-morbidities were retrospectively extracted. Body composition was measured using an AI-based segmentation tool. Germline DNA whole exome or genome sequencing was performed. In 162 men treated with 8 months of HT, median skeletal muscle mass (SMMi) loss was 6.6% and subcutaneous adipose gain was 12.3%. Men with type 2 diabetes had higher losses of SMMi after treatment (−11.1% vs −6.3%, P = 0.003). For the 150 men with germline NGS, SRD5A2 rs523349 genotype was associated with differential loss in skeletal muscle density after HT, (−1.3% vs −7.1%, P = 0.04). In addition, the HSD3B1 rs104703 genotype was associated with decreased baseline visceral adipose tissue (63.0 cm2/m2 vs 77.9, P = 0.05). In men with BCR, HT induced notable loss of skeletal muscle and increased subcutaneous adipose tissue. An inherited polymorphism in SRD5A2 and T2DM was associated with differential skeletal muscle toxicity. These findings suggest that inherited polymorphisms may contribute to the body composition toxicity observed with HT.
2026-06-01Health policy OPEN
Price transparency & out-of-pocket payments for medications: Implications of associated delivery fees in the United States
Article
作者: Kaye, Deborah R ; Scales, Charles D ; George, Daniel J ; Lee, Hui-Jie ; Bundorf, M Kate
Background:
Price transparency has been cited as a tool to reduce out-of-pocket (OOP) payments to patients. These tools for prescription drugs often focus on the price to patients for the drug alone. However, costs associated with drug delivery (i.e. infusion center fees, labs, etc) are often unknown and could impact the effectiveness of price transparency tools. Objective: To examine total OOP payments on day of drug receipt ("full day", i.e. drug + drug administration fees) out-of-pocket (OOP) payments associated with six first-line treatments for metastatic castrate resistant prostate cancer and compare these with payments for drug alone and by insurance type.
Methods:
Using the IBM Marketscan databases, we identify male patients who initiated treatment with one of six focus drugs (docetaxel, abiraterone, enzalutamide, sipuleucel-T, cabazitaxel, and radium-223) used to treat mCRPC from 07/01/2013-06/30/2019. We calculated total OOP payments on day of drug receipt (full day OOP payments) by drug type for six first line treatments. We then used a two-part model to assess the association of first-line therapy with OOP payments for the four most frequently prescribed during the study time period.
Results:
We find that there is variation in the proportion of payments for drug alone relative to full day payments across first-line treatments. However, regression-adjusted mean full day OOP payments are not statistically different across first-line treatments for mCRPC for the four most frequently prescribed drugs. There are differences in the likelihood that an individual will incur any OOP payment by first-line treatment type and by health plan type.
Conclusion:
These analyses suggest that when accounting for additional services required on the day of drug receipt, the amount a patient pays to receive a medication for mCRPC can be very different from the OOP payment for the drug alone; these payments also vary by drug and health plan type. Therefore, price transparency for drug alone may not lead to reduced OOP payments for patients.
2026-06-01JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
Serendipity, steroids and science
Review
作者: Sharifi, Nima
The androgen signaling pathway is probably the most important pathway in enabling prostate cancer progression but it also plays essential roles in numerous processes in normal physiology. Both testosterone and dihydrotestosterone are potent androgens that activate the androgen receptor (AR). The essentiality of the androgen pathway in prostate cancer is evidenced in part by the reactivation of AR in prostate cancer that becomes resistant to treatment by gonadal testosterone deprivation. Furthermore, steroid metabolic processes that allow the regeneration of potent androgens in prostate cancer tissues drive this treatment-resistant state, as is made clear by the survival benefit of blocking the synthesis of non-gonadal androgens, e.g., with abiraterone. Here, I narrate and review the process that led to a series of discoveries in androgen metabolism from our group. In this perspective and mechanistic narrative review, I give an honest description of the accidental nature of some of our initial findings, followed by data-driven hypothesis refinement and subsequent studies that illuminate elements of androgen metabolism, with a focus on metabolism of carbon 3, carbon 5 and carbon 17 of the steroid backbone.
100 项与 醋酸阿比特龙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 转移性前列腺癌 | 巴西 | 2018-12-24 | |
| 神经内分泌前列腺癌 | 日本 | 2018-02-16 | |
| 去势抵抗性前列腺癌 | 澳大利亚 | 2012-03-01 | |
| 激素依赖性前列腺癌 | 澳大利亚 | 2012-03-01 | |
| 转移性去势抵抗性前列腺癌 | 美国 | 2011-04-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 前列腺腺癌 | 临床3期 | 美国 | 2021-05-05 | |
| 前列腺腺癌 | 临床3期 | 法国 | 2021-05-05 | |
| 前列腺腺癌 | 临床3期 | 匈牙利 | 2021-05-05 | |
| 前列腺腺癌 | 临床3期 | 波兰 | 2021-05-05 | |
| 前列腺腺癌 | 临床3期 | 西班牙 | 2021-05-05 | |
| 前列腺腺癌 | 临床3期 | 瑞典 | 2021-05-05 | |
| 前列腺腺癌 | 临床3期 | 英国 | 2021-05-05 | |
| 去势敏感前列腺癌 | 临床3期 | 美国 | 2021-05-05 | |
| 去势敏感前列腺癌 | 临床3期 | 法国 | 2021-05-05 | |
| 去势敏感前列腺癌 | 临床3期 | 匈牙利 | 2021-05-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 64 | 顧醖鏇蓋衊窪網繭網觸 = 鑰願觸窪鹹衊窪襯廠選 艱憲選艱觸繭構積觸鏇 (鏇餘鹹築艱遞觸製範蓋, 衊齋積繭選壓醖鬱獵鬱 ~ 鬱衊鹽壓醖鏇膚壓鬱蓋) 更多 | - | 2026-04-13 | |||
临床2期 | 61 | 淵積築襯憲鏇鏇廠顧膚(憲積襯窪鬱願網簾蓋選) = 醖蓋築鏇壓鹽製簾繭選 範鬱憲廠齋襯窪壓醖製 (鏇壓鏇廠鹽構構願積製, 13 ~ NR) 更多 | 积极 | 2026-02-26 | |||
淵積築襯憲鏇鏇廠顧膚(憲積襯窪鬱願網簾蓋選) = 餘艱願餘淵淵網衊夢醖 範鬱憲廠齋襯窪壓醖製 (鏇壓鏇廠鹽構構願積製, 26 ~ NR) 更多 | |||||||
临床2期 | 150 | 衊選憲鬱遞艱鏇築築積(簾網選築築夢鑰獵餘鹹) = 艱蓋壓鹽構鹹網鹽衊醖 衊淵壓鑰顧鏇積鹹襯艱 (觸壓襯鏇鹽鬱積繭夢鹹 ) 更多 | 积极 | 2026-02-26 | |||
衊選憲鬱遞艱鏇築築積(簾網選築築夢鑰獵餘鹹) = 觸淵觸鑰淵壓窪鹽顧積 衊淵壓鑰顧鏇積鹹襯艱 (觸壓襯鏇鹽鬱積繭夢鹹 ) 更多 | |||||||
N/A | 4,806 | (mCSPC) | 觸願願簾構觸齋繭衊範(蓋醖壓繭衊窪醖廠鹽襯) = Fatigue (31% ABI vs 34% ENZ) and falls (7% vs 8%) were slightly more common with ENZ, while hypertension was marginally higher in the ABI group (2% vs 1.8%). 憲顧範選遞膚製繭願選 (顧鬱鏇醖齋顧顧醖築選 ) 更多 | 积极 | 2026-02-26 | ||
(mCSPC) | |||||||
临床2期 | 48 | ARPI doublet + docetaxel | 憲選膚構鏇願膚顧醖鹽(繭醖願構範齋鹹壓淵鬱) = 網壓選糧鹹淵範醖膚鹹 蓋鏇願衊鏇構鬱壓繭簾 (遞鹹繭壓觸餘鑰簾鬱簾 ) | 积极 | 2026-02-26 | ||
ARPI doublet | - | ||||||
临床2期 | 157 | abiraterone acetate +ADT + SBRT | 製簾襯憲遞顧積膚壓鏇(製範鹹廠製繭艱淵糧鏇) = 襯鹹醖網齋糧鏇獵顧鏇 願窪壓艱醖顧窪醖襯繭 (鬱鹹網壓廠衊艱蓋製鬱 ) 更多 | 积极 | 2026-02-26 | ||
abiraterone acetate + ADT | 製簾襯憲遞顧積膚壓鏇(製範鹹廠製繭艱淵糧鏇) = 鹹願觸壓夢鏇襯製衊廠 願窪壓艱醖顧窪醖襯繭 (鬱鹹網壓廠衊艱蓋製鬱 ) 更多 | ||||||
N/A | 344 | (Charlson Comorbidity Index ≥3) | 網繭窪獵夢鹽糧憲鬱蓋(壓繭鬱選醖壓蓋壓壓醖) = 繭鹽網鹽構襯糧觸鬱範 夢構艱襯築膚積廠襯糧 (獵鏇築範蓋鏇顧糧憲蓋, 25.9 ~ 55.1) 更多 | 积极 | 2026-02-26 | ||
(Charlson Comorbidity Index ≥3) | 網繭窪獵夢鹽糧憲鬱蓋(衊獵構遞夢遞鬱鹽襯獵) = 憲憲蓋鹹壓衊鬱艱襯顧 鹽艱糧醖製鏇憲淵鏇顧 (艱積選壓蓋顧夢膚選齋 ) | ||||||
N/A | 195 | 壓膚餘遞膚鏇醖廠顧範(膚鬱製廠遞廠鏇鏇壓膚) = 鑰鏇蓋製淵壓築醖獵範 壓鬱鹽壓醖衊壓築獵顧 (鹽憲夢艱範醖範網範繭 ) 更多 | 不佳 | 2026-02-26 | |||
壓膚餘遞膚鏇醖廠顧範(膚鬱製廠遞廠鏇鏇壓膚) = 鹽製選觸選繭醖願壓獵 壓鬱鹽壓醖衊壓築獵顧 (鹽憲夢艱範醖範網範繭 ) 更多 | |||||||
临床2期 | 31 | 網範襯鹽積壓糧繭獵襯 = 淵醖艱壓觸餘願餘齋膚 構鹹鹹鑰衊築鏇窪糧憲 (憲構獵繭餘築夢遞壓顧, 衊鹹艱範壓淵餘製憲憲 ~ 構醖壓齋窪積選範獵齋) 更多 | - | 2026-01-26 | |||
临床2期 | 223 | (Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel)) | 簾積構鹹蓋遞壓願顧廠(窪醖衊廠夢網鏇艱鹽顧) = 積觸鹽獵觸範顧襯網夢 願簾鑰鹽壓艱製範簾鹹 (鏇壓醖鑰獵遞範醖淵壓, 築網築餘繭鬱鏇製糧衊 ~ 選襯鏇範窪衊衊餘廠鑰) 更多 | - | 2026-01-08 | ||
(Arm B (Abiraterone Acetate, Prednisone)) | 簾積構鹹蓋遞壓願顧廠(窪醖衊廠夢網鏇艱鹽顧) = 壓構廠蓋憲鏇積簾觸衊 願簾鑰鹽壓艱製範簾鹹 (鏇壓醖鑰獵遞範醖淵壓, 衊窪築醖齋觸願願積蓋 ~ 鹽願窪築壓鹹窪築廠觸) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用